Latest News
Latest Events
- Jan 23, 2023 at 8:30 AM EST
- Jan 11, 2023 at 11:15 AM EST
- Dec 7, 2022 at 11:00 AM EST
Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.
This website uses cookies to improve the site and user experience. By continuing to browse the site, you agree to accept our use of cookies. For more information, please review our cookie policy.